Cancer Vaccine

Tumor cell-pulsed dendritic cells extend survival of mice with T cell lymphoma

Published in Cancer Weekly, January 14th, 2003

by Maria G. Essig, MS, ELS, senior medical writer - Dendritic cells (DCs) pulsed with lysates of murine C6VL T cell lymphoma cells protected mice against a lethal dose of C6VL cells and significantly prolonged the survival of tumor-bearing mice, according to a report in the Journal of Immunology.

Erin Gatza, at the University of Michigan Medical School, and Craig Y. Okada, at the University of Michigan and Veterans Administration Ann Arbor Health Care Systems, compared the efficacy of C6VL-DC vaccines with that of vaccines containing a conjugate of the T-cell receptor (TCR) Id protein and keyhole limpet hemocyanin (KLH) with the adjuvant QS-21.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry